We track 186 programmes in the Business Chain catalogue. 72 of them are open to healthtech companies right now. That number is not a reason to feel good about your odds. Most of those 72 will reject a clinical or patient-facing product the moment a reviewer reads your eligibility section closely, because 'open to' and 'built for' are different claims. Here is how to tell them apart on this specific list, what the money actually costs you in each shape it comes in, and which single application I'd send this month if I only had time for one. Full list: businesschain.us/funds/category/healthtech.
Funds the sector vs. tolerates the sector
Rock Health is the one program on this list built around digital health as its identity, not as a vertical it occasionally funds. Its terms are not confirmed on the program site at the time of writing, which means you call them before you write anything, but a reviewer here has already seen a reimbursement model and a clinical workflow before yours arrived. Everything else on this list is a generalist accelerator or fund that lists healthtech as an accepted category inside a much wider mandate.
gener8tor ($100,000 for 7.5% equity, rolling applications), PearX ($500K-$2M, applications accepted year round across two cohorts), Dreamit Ventures ($50,000-$100,000 for 6% equity), Techstars ($120,000) and Kickstart Fund (pre-seed and seed checks, amount undisclosed) will all take a healthtech application. None of them were built for one. Read their eligibility pages for the word 'vertical' or 'sector agnostic.' If it's there, you are competing against fintech and consumer apps for the same check, and your clinical validation story needs to do more selling than it would at Rock Health.
The three shapes the money takes, and what each one costs you
- Equity for cash. gener8tor ($100,000 for 7.5%), Dreamit ($50,000-$100,000 for 6%), Startmate (A$120,000 investment, applications close November 1, 2026 11:59pm AEDT, program runs February 1 to May 7, 2027) and SOSV / Orbit Startups ($150,000 on a SAFE, no fixed deadline stated) buy a fixed stake for a fixed sum before you know what your clinical data will say. The cost is dilution you've locked in at a pre-clinical valuation, which is expensive if your Series A comes in high.
- Non-dilutive grants with restricted spending. SCRA Startup & Acceleration Grants (up to $25,000 Startup or $50,000 Acceleration, rolling basis) and Michigan Business Accelerator Fund ($7,000-$15,000) don't touch your cap table, but the money is tied to specific line items and milestones, and you'll file progress reports to keep the next tranche moving. The EIC Accelerator grant component (below EUR 2.5 million for 24 months) carries the same reporting load at a much larger scale, plus its own investment component layered on top.
- Venture checks with no fixed terms published. Rock Health, PearX ($500K-$2M) and Kickstart Fund sit here. The cost isn't written on the program page because it's negotiated per deal, which means your leverage depends entirely on how far along your clinical evidence already is when you walk in.
The line in the eligibility text that knocks out most clinical applicants
It's TRL, not traction. The EIC Accelerator states its grant applies at TRL 6-8, meaning your technology has to already be validated in a relevant or operational environment before they'll fund it further. Most clinical-stage health products applying to any accelerator are still below that, sitting at prototype or early pilot, which is exactly where the money would be most useful. Read that line as a hard filter, not a guideline: if your device or software hasn't been tested in the setting it's meant to run in, EIC is not your next move regardless of how strong the science is. SCRA and the Michigan Business Accelerator Fund carry a quieter version of the same filter through state presence requirements buried in their program pages, so check residency before you spend a week on the application.
If you can only send one application this month
Send it to Rock Health. It is the only program on this list where the eligibility text is written for your product category, not adjacent to it, and that changes what a strong application looks like. You're not spending half your word count explaining why a reimbursement-dependent business model is normal. Confirm their current terms directly before you apply since the program site doesn't state them. If Rock Health's cycle doesn't line up with your month, your second move is SCRA at up to $50,000 non-dilutive on a rolling basis, because it costs you no equity and no calendar deadline to miss, not because it was built for healthtech specifically.